Voyager Therapeutics
Market Cap
US$324.8m
Last Updated
2021/01/19 23:47 UTC
Data Sources
Company Financials +
Executive Summary
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 25% per year for the next 3 years
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Voyager Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VYGR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: VYGR's weekly volatility (10%) has been stable over the past year.
Market Performance
7 Day Return
-0.2%
VYGR
4.5%
US Biotechs
0.3%
US Market
1 Year Return
-35.2%
VYGR
40.6%
US Biotechs
21.1%
US Market
Return vs Industry: VYGR underperformed the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: VYGR underperformed the US Market which returned 19.5% over the past year.
Shareholder returns
| VYGR | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.2% | 4.5% | 0.3% |
| 30 Day | -1.3% | 6.8% | 3.3% |
| 90 Day | -20.9% | 27.2% | 14.2% |
| 1 Year | -35.2%-35.2% | 42.9%40.6% | 23.8%21.1% |
| 3 Year | -58.9%-58.9% | 28.8%22.1% | 45.0%35.4% |
| 5 Year | -25.0%-25.0% | 51.3%39.6% | 127.7%102.3% |
Long-Term Price Volatility Vs. Market
How volatile is Voyager Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Voyager Therapeutics' (NASDAQ:VYGR) Stock Price Has Reduced 65% In The Past Five Years1 month ago | Simply Wall St
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?2 months ago | Simply Wall St
We're Not Very Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn RateValuation
Is Voyager Therapeutics undervalued compared to its fair value and its price relative to the market?
8.01x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: VYGR ($8.67) is trading above our estimate of fair value ($2.12)
Significantly Below Fair Value: VYGR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VYGR is good value based on its PE Ratio (8x) compared to the US Biotechs industry average (33.1x).
PE vs Market: VYGR is good value based on its PE Ratio (8x) compared to the US market (21x).
Price to Earnings Growth Ratio
PEG Ratio: VYGR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: VYGR is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Voyager Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
-25.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VYGR's earnings are forecast to decline over the next 3 years (-25% per year).
Earnings vs Market: VYGR's earnings are forecast to decline over the next 3 years (-25% per year).
High Growth Earnings: VYGR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: VYGR's revenue is expected to decline over the next 3 years (-13.5% per year).
High Growth Revenue: VYGR's revenue is forecast to decline over the next 3 years (-13.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VYGR is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Voyager Therapeutics performed over the past 5 years?
-1.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VYGR has high quality earnings.
Growing Profit Margin: VYGR became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: VYGR has become profitable over the past 5 years, growing earnings by -1.1% per year.
Accelerating Growth: VYGR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: VYGR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: VYGR's Return on Equity (24.1%) is considered high.
Next Steps
Financial Health
How is Voyager Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: VYGR's short term assets ($216.3M) exceed its short term liabilities ($42.1M).
Long Term Liabilities: VYGR's short term assets ($216.3M) exceed its long term liabilities ($61.5M).
Debt to Equity History and Analysis
Debt Level: VYGR is debt free.
Reducing Debt: VYGR had no debt 5 years ago.
Debt Coverage: VYGR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VYGR has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Voyager Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VYGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VYGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VYGR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VYGR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VYGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
G. Turenne (46 yo)
2.5yrs
Tenure
US$2,844,090
Compensation
Mr. G. Andre Turenne has been President, Chief Executive Officer and Director at Voyager Therapeutics, Inc. since July 16, 2018. Mr. Turenne has proven leadership, strategic vision, and a strong track reco...
CEO Compensation Analysis
Compensation vs Market: G.'s total compensation ($USD2.84M) is above average for companies of similar size in the US market ($USD1.66M).
Compensation vs Earnings: G.'s compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.84m | 0.11% $ 373.0k | |
| Senior VP & General Counsel | 1.75yrs | US$3.34m | 0.017% $ 54.5k | |
| Chief Medical Officer and Head of Research & Development | 2yrs | US$3.82m | 0.017% $ 56.4k | |
| Executive Science Advisor & Director | 6.33yrs | US$578.18k | 2.3% $ 7.5m | |
| no data | no data | no data | ||
| no data | no data | no data | ||
| no data | no data | no data | ||
| no data | no data | no data | ||
| CFO & Principal Accounting Officer | 2.58yrs | no data | 0.035% $ 114.9k | |
| Vice President of Investor Relations | 1.17yrs | no data | no data | |
| Chief Human Resources Officer | 0.33yr | no data | no data | |
| Chief Business Officer | 1.17yrs | no data | no data |
1.9yrs
Average Tenure
56yo
Average Age
Experienced Management: VYGR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.84m | 0.11% $ 373.0k | |
| Executive Science Advisor & Director | 6.33yrs | US$578.18k | 2.3% $ 7.5m | |
| Consultant & Member of Scientific Advisory Board | 1.58yrs | US$1.81m | no data | |
| Independent Director | 7yrs | US$601.18k | 0.20% $ 664.0k | |
| Independent Director | 7.58yrs | US$578.18k | 0.098% $ 318.2k | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Independent Director | 4yrs | US$583.18k | 0.013% $ 43.4k | |
| Independent Director | 5.33yrs | US$597.52k | no data | |
| Independent Chairman | 1.58yrs | US$644.18k | no data | |
| Independent Director | 0.33yr | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.5yrs
Average Tenure
65yo
Average Age
Experienced Board: VYGR's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Voyager Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Voyager Therapeutics, Inc.
- Ticker: VYGR
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$324.828m
- Shares outstanding: 37.47m
- Website: https://www.voyagertherapeutics.com
Number of Employees
Location
- Voyager Therapeutics, Inc.
- 75 Sidney Street
- Cambridge
- Massachusetts
- 2139
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| VYGR | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Nov 2015 |
| VT6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2015 |
| VYGR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Nov 2015 |
Biography
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead clinical candidate i...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/19 23:47 |
| End of Day Share Price | 2021/01/19 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.